Company Filing History:
Years Active: 2024
Title: **Chi Zhou: Innovator in Metabolic Regulation**
Introduction
Chi Zhou is a notable inventor based in Shanghai, China. He has made significant contributions in the field of biopharmaceuticals, specifically focusing on innovations aimed at regulating blood glucose and lipid levels. His work represents a vital advancement in treating metabolic disorders, which have become increasingly prevalent in today's society.
Latest Patents
Zhou holds a patent for a **dual-function protein for lipid and blood glucose regulation**. This innovative protein consists of a human GLP-1 analog combined with human FGF21. The invention outlines a method for preparing this dual-function protein and its application in creating biological substances intended for treating conditions such as type 2 diabetes, obesity, dyslipidemia, fatty liver disease, and metabolic syndrome. The dual-function protein has been designed to synergistically manage blood glucose and lipid levels in vivo, addressing multiple issues faced by patients with type 2 diabetes, including lowering blood glucose, alleviating hepatic steatosis, reducing body weight, and improving metabolic disorders related to circulating lipids.
Career Highlights
Chi Zhou is currently employed at Ampsource Biopharma Shanghai Inc., where he utilizes his expertise to drive research and development forward. His commitment to innovation in the biopharmaceutical sector has positioned him as an influential figure, paving the way for new therapeutic approaches in the management of metabolic disorders.
Collaborations
Throughout his career, Zhou has collaborated with esteemed colleagues including Zhao Dong and Xiong Feng. These partnerships have fostered an environment of creativity and innovation, leading to advancements in their joint research initiatives aimed at improving patient outcomes in metabolic health.
Conclusion
In summary, Chi Zhou exemplifies the spirit of innovation in the biopharmaceutical field. His contributions through patents and collaborations have the potential to significantly impact the treatment of metabolic disorders, offering hope and improved health outcomes for patients worldwide.